It is necessary to clarify whether the activation of CB1R is beneficial or harmful and how it affects the development of pulmonary fibrosis for the pharmaceutical development of CB1R agonists or antagonists and their potential therapeutic uses in pulmonary fibrosis. This evidence concerns the gene CNR1 and pulmonary fibrosis.